<DOC>
	<DOCNO>NCT00475033</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability immunogenicity 13-valent pneumococcal conjugate vaccine healthy infant give routine pediatric vaccination Canada . Immune response induce infant series ( NeisVac-C® Pentacel® ) toddler dose ( NeisVac-C® ) routine pediatric vaccine administer 13-valent pneumococcal conjugate vaccine study noninferiority immune response administer 7-valent pneumococcal conjugate vaccine . Safety profile immunogenicity 13-valent pneumococcal conjugate vaccine also evaluate .</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy 2month old infant ( 42 98 day ) Available duration study reachable telephone Previous vaccination license investigational pneumococcal , Hib conjugate , diphtheria , tetanus , pertussis , polio , meningococcal vaccine Previous anaphylactic reaction vaccine vaccinerelated component . Bleeding disorder , immune deficiency suppression , significant chronic congenital disease Receipt blood product gamma globulin</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>